FDA Approves Zoryve Cream for Treating Atopic Dermatitis in Young Children
The FDA has approved Zoryve cream for treating mild-to-moderate atopic dermatitis in children aged 2 to 5, offering a non-steroid topical option backed by clinical trials showing rapid symptom improvement.
The U.S. Food and Drug Administration (FDA) has granted approval for Zoryve (roflumilast) cream 0.05% as a topical treatment for children aged 2 to 5 years with mild-to-moderate atopic dermatitis. This approval marks a significant advancement in pediatric eczema management, offering a non-steroid option that can be applied once daily over any area of the body. The decision was based on clinical trial data demonstrating that Zoryve swiftly reduced the severity and extent of eczema symptoms. Approximately 40% of pediatric participants achieved a 75% improvement in eczema severity scores, and over one-third (35%) experienced meaningful relief from itching within four weeks.
Young children are particularly susceptible to the discomfort caused by atopic dermatitis due to their underdeveloped immune systems and skin barriers, which can result in ongoing skin issues and reduced quality of life. As Korey Capozza, founder and executive director at Global Parents of Eczema Research, explained, this condition impacts not just the child's skin but also affects family dynamics through sleep disturbances, emotional stress, and social challenges.
The approval was granted to Arcutis Biotherapeutics and provides families with a new therapeutic option that avoids the use of steroids, which are traditionally employed in eczema treatment. Overall, Zoryve’s approval is a promising step forward in the management of pediatric atopic dermatitis, aiming to improve the comfort and well-being of young children affected by this chronic condition.
Source: https://medicalxpress.com/news/2025-10-fda-zoryve-atopic-dermatitis-young.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
FANSS Study Confirms Feasibility of Lung Cancer Screening in U.S. for Asian Female Nonsmokers
The FANSS study reveals the promise of low-dose CT scans in detecting lung cancer among Asian female nonsmokers, challenging current screening guidelines and highlighting the need for more inclusive criteria.
Discovery of Key Proteins Associated with Rare Autoimmune Vasculopathy
Researchers have identified two proteins, CCN1 and CCN2, that play a crucial role in blood vessel thickening in autoimmune vasculopathy, a complication of antiphospholipid syndrome, opening new avenues for targeted treatments.
Innovative Imaging Technique Identifies Multiple Subtypes of Triple-Negative Breast Cancer
A novel imaging strategy targeting the tumor microenvironment enhances detection of diverse triple-negative breast cancer subtypes, supporting better diagnosis and personalized treatment planning.
MRI Technique Enhances Identification of High-Risk Cardiac Sarcoidosis Patients for Implantable Defibrillators
Innovative MRI-based imaging techniques are improving the identification of cardiac sarcoidosis patients at high risk of sudden death, promoting targeted ICD therapy for better outcomes.